Dorzolamide-timolol significantly reduces post-injection intraocular pressure spikes, showing its potential as a preventive measure.
The trial demonstrated a mean intraocular pressure of 9.20 mmHg in the trial group, compared to 15.37 mmHg in controls, indicating a significant difference (p < 0.001).
Randomized controlled trial comparing intraocular pressure changes after intravitreal bevacizumab with and without prophylaxis.
Routine prophylactic use of dorzolamide-timolol may be beneficial for patients with proliferative diabetic retinopathy to manage intraocular pressure.